Central Nervous System Disorders Therapeutics Global Market Growth & Demands by 2020
About Central Nervous System Disorders Therapeutics (CNS) disorders
CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.
Read more at: http://www.researchbeam.com/global-central-nervous-system-disorders-therapeutics-2016-2020-market
Researchbeam’s analysts forecast the Global Central Nervous System (CNS) Disorders Therapeutics Market To Grow At A CAGR Of 3.38% During The Period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Researchbeam's report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Novartis
Other prominent vendors
• AB Science
• AbbVie
• Abital Pharma
• Acorda Therapeutics
• Active Biotech
• Adamas Pharmaceuticals
• Addex Therapeutics
• Akorn
• Alcobra
• Alexza Pharmaceuticals
• Alkermes
• Amarantus
• Aprecia Pharmaceuticals
• Archer Pharmaceuticals
• Astellas
• AstraZeneca
• Aurobindo Pharma
• Auspex Pharmaceuticals
• Avanir Pharmaceuticals
• Biscayne Pharmaceuticals
• Boehringer Ingelheim
• Cerecor
• Concordia
• Convergence Pharmaceuticals
• Curemark
• CURx Pharmaceuticals
• Dainippon Sumitomo Pharma
• Dart NeuroScience
• Delpor
• Desitin Arzneimittel
• D-Pharm
• Edgemont Pharmaceuticals
• Endo International
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre-Kramer Pharmaceuticals
• Forum Pharmaceuticals
• Gedeon Richter
• Glenmark
• Grupo Ferrer Internacional
• GW Pharmaceuticals
• H. Lundbeck
• Hisamitsu
• Impax
• Insero Health
• INSYS Therapeutics
• Intellipharmaceutics
• Intra-Cellular Therapies
• Ipsen
• Kyowa Hakko Kirin
• Ligand Pharmaceuticals
• Lupin
• MarcoPolo Pharmaceuticals
• Marinus Pharmaceuticals
• Meda AB
• Merck
• Mitsubishi Tanabe
• MSI Methylation Sciences
• Mylan
• Naurex
• Neuralstem
• Neurelis
• Neurovance
• Nobelpharma
• Noven Pharmaceuticals
• Omeros
• Opexa
• Opko Health
• Orion
• Ophelia Pharmaceutical
• Otsuka Pharmaceuticals
• Palobiofarma
• Par Pharmaceuticals
• Pierre Fabre
• Prana Biotechnology
• Raptor Pharmaceutical
• Reviva Pharmaceuticals
• SAGE Therapeutics
• Sanofi
• SciFlour
• Sedor Pharmaceuticals
• Shire
• Siena Biotech
• SK Biopharmaceuticals
• SOM Biotech
• Somerset Pharmaceuticals
• STADA Arzneimittel
• Sun Pharmaceuticalc
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Suven
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Tris Pharma
• Turing Pharmaceuticals
• UCB
• US WorldMeds
• Valeant Pharmaceuticals
• Zinfandel Pharmaceuticals
• Zogenix
Market driver
• New DMD approvals for AD, PD, and MS
• For a full, detailed list, view our report
Market challenge
• High failure rates of late-stage products in clinical trials
• For a full, detailed list, view our report
Market trend
• Increased uptake of new-generation drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Request report sample @ http://www.researchbeam.com/global-central-nervous-system-disorders-therapeutics-2016-2020-market/enquire-about-report
Table of Contents
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Pipeline portfolio
• Phase III pipeline portfolio: Global CNS disorders therapeutics market
• Phase II pipeline portfolio: Global CNS disorders therapeutics market
• Phase I pipeline portfolio: Global CNS disorders therapeutics market
• Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of disease
• Global depression drugs market
• Global MS drugs market
• Global schizophrenia drugs market
• Global bipolar disorder therapeutics market
• Global AD drugs market
• Global epilepsy drugs market
• Global PD drugs market
About Us:
With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
Contact Us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
U.S. & Canada Toll Free: + 1-800-910-6452
International: + 1-503-894-6022
UK: + 44-845-528-1300
India: +91 20 66346070
Fax: +1 (855) 550-5975
Email: help@researchbeam.com
Web: http://www.researchbeam.com/
CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.
Read more at: http://www.researchbeam.com/global-central-nervous-system-disorders-therapeutics-2016-2020-market
Researchbeam’s analysts forecast the Global Central Nervous System (CNS) Disorders Therapeutics Market To Grow At A CAGR Of 3.38% During The Period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Researchbeam's report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Novartis
Other prominent vendors
• AB Science
• AbbVie
• Abital Pharma
• Acorda Therapeutics
• Active Biotech
• Adamas Pharmaceuticals
• Addex Therapeutics
• Akorn
• Alcobra
• Alexza Pharmaceuticals
• Alkermes
• Amarantus
• Aprecia Pharmaceuticals
• Archer Pharmaceuticals
• Astellas
• AstraZeneca
• Aurobindo Pharma
• Auspex Pharmaceuticals
• Avanir Pharmaceuticals
• Biscayne Pharmaceuticals
• Boehringer Ingelheim
• Cerecor
• Concordia
• Convergence Pharmaceuticals
• Curemark
• CURx Pharmaceuticals
• Dainippon Sumitomo Pharma
• Dart NeuroScience
• Delpor
• Desitin Arzneimittel
• D-Pharm
• Edgemont Pharmaceuticals
• Endo International
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre-Kramer Pharmaceuticals
• Forum Pharmaceuticals
• Gedeon Richter
• Glenmark
• Grupo Ferrer Internacional
• GW Pharmaceuticals
• H. Lundbeck
• Hisamitsu
• Impax
• Insero Health
• INSYS Therapeutics
• Intellipharmaceutics
• Intra-Cellular Therapies
• Ipsen
• Kyowa Hakko Kirin
• Ligand Pharmaceuticals
• Lupin
• MarcoPolo Pharmaceuticals
• Marinus Pharmaceuticals
• Meda AB
• Merck
• Mitsubishi Tanabe
• MSI Methylation Sciences
• Mylan
• Naurex
• Neuralstem
• Neurelis
• Neurovance
• Nobelpharma
• Noven Pharmaceuticals
• Omeros
• Opexa
• Opko Health
• Orion
• Ophelia Pharmaceutical
• Otsuka Pharmaceuticals
• Palobiofarma
• Par Pharmaceuticals
• Pierre Fabre
• Prana Biotechnology
• Raptor Pharmaceutical
• Reviva Pharmaceuticals
• SAGE Therapeutics
• Sanofi
• SciFlour
• Sedor Pharmaceuticals
• Shire
• Siena Biotech
• SK Biopharmaceuticals
• SOM Biotech
• Somerset Pharmaceuticals
• STADA Arzneimittel
• Sun Pharmaceuticalc
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Suven
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Tris Pharma
• Turing Pharmaceuticals
• UCB
• US WorldMeds
• Valeant Pharmaceuticals
• Zinfandel Pharmaceuticals
• Zogenix
Market driver
• New DMD approvals for AD, PD, and MS
• For a full, detailed list, view our report
Market challenge
• High failure rates of late-stage products in clinical trials
• For a full, detailed list, view our report
Market trend
• Increased uptake of new-generation drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Request report sample @ http://www.researchbeam.com/global-central-nervous-system-disorders-therapeutics-2016-2020-market/enquire-about-report
Table of Contents
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Pipeline portfolio
• Phase III pipeline portfolio: Global CNS disorders therapeutics market
• Phase II pipeline portfolio: Global CNS disorders therapeutics market
• Phase I pipeline portfolio: Global CNS disorders therapeutics market
• Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of disease
• Global depression drugs market
• Global MS drugs market
• Global schizophrenia drugs market
• Global bipolar disorder therapeutics market
• Global AD drugs market
• Global epilepsy drugs market
• Global PD drugs market
About Us:
With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
Contact Us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
U.S. & Canada Toll Free: + 1-800-910-6452
International: + 1-503-894-6022
UK: + 44-845-528-1300
India: +91 20 66346070
Fax: +1 (855) 550-5975
Email: help@researchbeam.com
Web: http://www.researchbeam.com/